712 related articles for article (PubMed ID: 17698131)
41. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.
Ward JF; Nakanishi H; Pisters L; Babaian RJ; Troncoso P
BJU Int; 2009 Aug; 104(4):490-7. PubMed ID: 19220260
[TBL] [Abstract][Full Text] [Related]
42. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
[TBL] [Abstract][Full Text] [Related]
43. Prediction of extraprostatic extension in men with biopsy Gleason score of 8 or greater.
Nakanishi H; Troncoso P; Babaian RJ
J Urol; 2008 Dec; 180(6):2441-5; discussion 2445-6. PubMed ID: 18930495
[TBL] [Abstract][Full Text] [Related]
44. Improved accuracy for predicting the Gleason score of prostate cancer by increasing the number of transrectal biopsy cores.
Miyake H; Kurahashi T; Takenaka A; Hara I; Fujisawa M
Urol Int; 2007; 79(4):302-6. PubMed ID: 18025846
[TBL] [Abstract][Full Text] [Related]
45. The percentage of positive biopsy cores as a predictor of disease recurrence in patients with prostate cancer treated with radical prostatectomy.
Antunes AA; Srougi M; Dall'Oglio MF; Crippa A; Campagnari JC; Leite KR
BJU Int; 2005 Dec; 96(9):1258-63. PubMed ID: 16287441
[TBL] [Abstract][Full Text] [Related]
46. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.
Whitman EJ; Groskopf J; Ali A; Chen Y; Blase A; Furusato B; Petrovics G; Ibrahim M; Elsamanoudi S; Cullen J; Sesterhenn IA; Brassell S; Rittenhouse H; Srivastava S; McLeod DG
J Urol; 2008 Nov; 180(5):1975-8; discussion 1978-9. PubMed ID: 18801539
[TBL] [Abstract][Full Text] [Related]
47. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
[TBL] [Abstract][Full Text] [Related]
48. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy?
Loeb S; Yu X; Nadler RB; Roehl KA; Han M; Hawkins SA; Catalona WJ
J Urol; 2007 Jan; 177(1):102-6; discussion 106. PubMed ID: 17162013
[TBL] [Abstract][Full Text] [Related]
49. Expectant management of nonpalpable prostate cancer with curative intent: preliminary results.
Carter HB; Walsh PC; Landis P; Epstein JI
J Urol; 2002 Mar; 167(3):1231-4. PubMed ID: 11832703
[TBL] [Abstract][Full Text] [Related]
50. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer.
D'Amico AV; Hui-Chen M; Renshaw AA; Sussman B; Roehl KA; Catalona WJ
J Urol; 2006 Dec; 176(6 Pt 2):S11-5. PubMed ID: 17084157
[TBL] [Abstract][Full Text] [Related]
51. Prostate needle biopsies: multiple variables are predictive of final tumor volume in radical prostatectomy specimens.
Poulos CK; Daggy JK; Cheng L
Cancer; 2004 Aug; 101(3):527-32. PubMed ID: 15274065
[TBL] [Abstract][Full Text] [Related]
52. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy.
Chuang AY; Nielsen ME; Hernandez DJ; Walsh PC; Epstein JI
J Urol; 2007 Oct; 178(4 Pt 1):1306-10. PubMed ID: 17698141
[TBL] [Abstract][Full Text] [Related]
53. Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy.
Bañez LL; Sun L; Trock BJ; Han M; Partin AW; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Moul JW; Freedland SJ
J Urol; 2009 Aug; 182(2):491-6; discussion 496-8. PubMed ID: 19524974
[TBL] [Abstract][Full Text] [Related]
54. Changing nature of high risk patients undergoing radical prostatectomy.
Kane CJ; Presti JC; Amling CL; Aronson WJ; Terris MK; Freedland SJ;
J Urol; 2007 Jan; 177(1):113-7. PubMed ID: 17162017
[TBL] [Abstract][Full Text] [Related]
55. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
Miyake H; Sakai I; Harada K; Hara I; Eto H
Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
[TBL] [Abstract][Full Text] [Related]
56. Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.
Varkarakis J; Pinggera GM; Sebe P; Berger A; Bartsch G; Horninger W
Urology; 2004 Feb; 63(2):337-41. PubMed ID: 14972485
[TBL] [Abstract][Full Text] [Related]
57. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
[TBL] [Abstract][Full Text] [Related]
58. Percent tumor involvement and risk of biochemical progression after radical prostatectomy.
Rampersaud EN; Sun L; Moul JW; Madden J; Freedland SJ
J Urol; 2008 Aug; 180(2):571-6; discussion 576. PubMed ID: 18554662
[TBL] [Abstract][Full Text] [Related]
59. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
60. Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database.
Buschemeyer WC; Hamilton RJ; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Freedland SJ
J Urol; 2008 Jan; 179(1):124-9; discussion 129. PubMed ID: 17997433
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
